Description
Giotrif (Afatinib) 40mg Online
Giotrif (Afatinib) is used For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
GIOTRIF is a medicine that contains the active substance afatinib. It works by blocking the activity of a group of proteins called the ErbB family (including EGFR [epidermal growth factor receptor or ErbB1], HER2 [ErbB2], ErbB3, and ErbB4). These proteins are involved in the growth and spread of cancer cells, and can be affected by changes (mutations) in the genes that produce them. By blocking the activity of these proteins this medicine can inhibit the growth and spread of cancer cells.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should avoid becoming pregnant while taking this medicine.
If you could become pregnant, you should use adequate birth control methods during treatment and for at least 1 month after taking the last dose of this medicine. This is because there may be a risk that an unborn baby is harmed. If you become pregnant while receiving this medicine, you should immediately inform your doctor. Your doctor will decide with you whether treatment should be continued or not.
If you plan to become pregnant after taking the last dose of this medicine, you should ask your doctor for advice as your body may not have fully eliminated this medicine. Do not breastfeed while taking this medicine as a risk to the breast-fed child cannot be excluded. If you experience treatment-related symptoms affecting your eyesight (e.g. redness and/or irritation of the eye, dry eye, tearing, light sensitivity) or your ability to concentrate and react, it is recommended that you do not drive or use machines until the side effect disappears.
